Biologic therapies for asthma in underserved populations.
Biologic therapies for asthma in underserved populations.
复制标题
DOI：
10.1016/s0140-6736(22)01383-6
复制
发表时间：
2022-08-13
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
在美国，生活在贫困城市环境中的黑人和西班牙裔儿童面临着不成比例的哮喘负担，他们的发病率和死亡率是全国最高的。1在这些人群中，伴随着严重嗜酸性哮喘的反复恶化可导致肺功能丧失、哮喘严重程度增加，并在成年早期发展为固定性阻塞性肺疾病。2、3令人担忧的是，在这些儿童中，很大一部分儿童的传统指南指导疗法，如皮质类固醇和长效β激动剂，并不能改善哮喘控制。因此，确定新的治疗策略是生活在城市地区、服务不足的黑人和西班牙裔儿童的一个重要的未得到满足的需求。生物疗法(即用活的动物、植物或细胞创造的疗法)提供了一个令人信服的选择。美波利单抗是一种人源化的单抗，可直接与2型细胞因子白介素5结合，从而
Black and Hispanic children living in disadvantaged urban environments in the USA face a disproportionate burden of asthma, experiencing the highest rates of morbidity and mortality in the country. 1 The repeated exacerbations that accompany severe eosinophilic asthma in these populations can lead to loss of lung function, increased asthma severity, and progression to a pattern of fixed obstructive lung disease by early adulthood. 2, 3 Worryingly, in a substantial proportion of these children, conventional guideline-directed therapies, such as corticosteroids and long-acting β agonists, do not improve asthma control. Consequently, the identification of novel therapeutic strategies represents an important unmet need for underserved Black and Hispanic children living in urban areas. 4 Biologic therapies (ie, treatments created from living animals, plants, or cells5) provide a compelling option. Mepolizumab is a humanised monoclonal antibody that binds directly to type 2 cytokine interleukin-5 to